I was once the proud owner of a gadget from the early 2000s. A belt you wrapped around your midsection, switched on, and supposedly watched the vibrations melt the fat away. Predictably, it did not work. In fact, it never could have. Still, at the time I wanted it to work so much that, for a moment, I set aside everything I knew as a physician about how muscle and metabolism actually respond to real stimulus. Even after decades of medical training, hope can turn us all into fools.
From this experience, I react negatively every time I see another easy answer to a complex health issue, such as an “exercise in a pill” claim, show up in my inbox. Usually, I scroll past it and ignore it. There are important research studies in which to better invest my time. This month, though, one story made me stop because it seemed to offer a more serious approach to that familiar idea.
In 2022, researchers at Stanford, led by Jonathan Long, discovered a molecule called Lac-Phe, short for lactate-phenylalanine, that is released into the bloodstream during intense exercise. Lac-Phe suppresses appetite and reduces obesity in animal models. The problem is that Lac-Phe clears from the body almost as fast as it appears. You can’t bottle a molecule that is cleared from the bloodstream before it does its job.
Scientists at a Boulder biotech called Enveda used AI-driven technology to produce an oral compound, ENV-308, designed to mimic Lac-Phe’s effects but last long enough to matter as a once-daily pill. Phase 1 results in 88 healthy volunteers showed it was well tolerated, notably without the nausea and GI distress that drive so many patients off glucagon-like peptide-1 (GLP-1) drugs. It also lowered circulating leptin, an early signal that the compound is biologically relevant to appetite and metabolic regulation. In animal studies, it preserved lean muscle during weight loss and prevented the rebound weight gain so common after stopping GLP-1 therapy, which would matter greatly if those results held true in people.
Real physician voices, twice a week
Free, and one click to unsubscribe.
That last point is the real challenge. Many patients who lose weight on GLP-1s end up regaining it, often with more muscle loss than they expected. This “yo-yo” cycle is now recognized as a potential risk in its own right. If we could offer a compound that preserves muscle and regulates appetite after a patient comes off a GLP-1, we would be addressing a significant unmet need in obesity care. The consequences of failing to do so are already familiar.
But after more than four decades in medicine, and more than a few decades chasing my own fitness goals, I have seen this story play out before. I have a pretty good idea how it usually ends, and this is the point.
GW501516, a peroxisome proliferator-activated receptor delta (PPAR-delta) agonist that activates some of the same endurance-training pathways, showed genuine promise in animals, but long-term rodent studies revealed a cancer signal that shelved it. It never went away, though. It resurfaced as “Cardarine,” sold on the internet to athletes willing to gamble their health on a drug that failed for exactly the reason they were told to ignore.
Sirtuin activators, molecules meant to mimic resveratrol’s effects on longevity and metabolism, drove a well-funded biotech, hundreds of millions of dollars in investment, and a wave of magazine covers in the 2000s. Human trials never matched the hype, and the lead program was eventually discontinued.
Myostatin inhibitors were meant to build muscle, much like resistance training does. In trials, they did increase muscle mass. But they didn’t consistently deliver strength or function, the real reasons muscle matters, especially as we age. As someone who spends a fair amount of time in the gym, I can confirm that muscle without function isn’t much of a victory.
The pattern is all too familiar: a biological mechanism, some promising early data, and then a disappointing gap between “this pathway matters” and “this pill can actually do what exercise does for the human body.” That gap is the real issue here, and in my experience, it’s always been wider than we care to admit.
So where does that leave ENV-308 in this story?
This is certainly further along than that old belt gathering dust in my closet. The mechanism is rooted in real, published exercise physiology, not just marketing promises. The safety data so far is encouraging. Still, this trial used healthy volunteers and didn’t measure weight loss, muscle preservation, or any outcomes that truly matter to patients and to those of us who care about health span and function. Those studies are still to come, and until they do, the question is whether ENV-308 can close the gap that has defeated so many predecessors. Phase 1 studies are focused on safety, not efficacy. Though they offer some indicators of potential, later clinical phases provide the design, statistical power, and standard analyses needed to assess any new drug’s long-term benefits and risks. Shortchanging this proven evaluation process through hype does not support balanced health outcomes.
I will be watching the Phase 2 data with interest, because a true adjunct to GLP-1 therapy that protects muscle and prevents rebound weight gain would absolutely change how I advise my patients. Still, after all these years in practice, and more than a few years trying to outsmart my own physiology, I have learned to be cautious. The question is not whether “mimics exercise” sounds appealing, but whether it can deliver what exercise actually does.
Exercise still does something no pill has replicated: It requires your active participation. Whatever ENV-308 turns out to be, it will not replace that. At best, it may bridge the gap for those already putting in the effort. I will be following this story, but in the meantime, I wouldn’t recommend dropping the weights or skipping your next workout.
Francisco M. Torres is an interventional physiatrist specializing in diagnosing and treating patients with spine-related pain syndromes. He is certified by the American Board of Physical Medicine and Rehabilitation and the American Board of Pain Medicine and can be reached at Florida Spine Institute and Wellness.
Dr. Torres was born in Spain and grew up in Puerto Rico. He graduated from the University of Puerto Rico School of Medicine. Dr. Torres performed his physical medicine and rehabilitation residency at the Veterans Administration Hospital in San Juan before completing a musculoskeletal fellowship at Louisiana State University Medical Center in New Orleans. He served three years as a clinical instructor of medicine and assistant professor at LSU before joining Florida Spine Institute in Clearwater, Florida, where he is the medical director of the Wellness Program.
Dr. Torres is an interventional physiatrist specializing in diagnosing and treating patients with spine-related pain syndromes. He is certified by the American Board of Physical Medicine and Rehabilitation and the American Board of Pain Medicine. He is a prolific writer and primarily interested in preventative medicine. He works with all of his patients to promote overall wellness.
